Summary & Overview
HCPCS S0017: Injection, Aminocaproic Acid, 5 Grams
HCPCS Level II code S0017 denotes a 5-gram injection of aminocaproic acid, an antifibrinolytic agent used to control or prevent bleeding. Nationally, this code matters for clinicians and payers because it identifies a specific high-dose medication administration event that can occur in outpatient infusion centers, hospital outpatient departments, and physician offices. Accurate coding affects claims processing, utilization tracking, and clinical supply management.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of coding context, typical sites of service, and clinical use of aminocaproic acid. The publication outlines common billing considerations and the operational context for administering a 5-gram injection, while noting where input data is not provided.
This report helps billing managers, compliance officers, and clinical administrators understand how S0017 is used across outpatient infusion and ambulatory care settings, what to expect in payer coverage discussions, and which operational elements are relevant for documentation and claims submission. Data not available in the input is identified as such for items not provided in the source context.
Billing Code Overview
HCPCS Level II code S0017 describes Injection, aminocaproic acid, 5 grams. This service represents administration of an antifibrinolytic agent used to reduce bleeding by inhibiting plasminogen activation. The service type is an injection/infusion medication administration. The typical site of service for this code is outpatient infusion or ambulatory care settings, including hospital outpatient departments, infusion centers, and physician offices.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult admitted for significant mucosal or surgical bleeding (for example, postoperative hemorrhage after cardiac surgery or severe oral mucosal bleeding) where antifibrinolytic therapy is indicated. The clinician orders S0017 — injection, aminocaproic acid, 5 grams — to achieve systemic antifibrinolytic effect. The clinical workflow: assessment of bleeding severity and hemodynamics; review of contraindications (active thromboembolic disease, disseminated intravascular coagulation without fibrinolysis, allergy); informed consent and documentation of indication in the medical record; preparation of the dose by pharmacy or nursing per facility protocol; IV administration (bolus or infusion per institutional dosing) with monitoring for adverse reactions (hypersensitivity, thrombosis, hypotension); post-administration reassessment of bleeding, laboratory studies (CBC, coagulation panel), and documentation of response in the chart. Typical sites of service include inpatient hospital (acute care), post-anesthesia care unit, and emergency department when used for acute hemorrhage. Typical patient scenario: a 67-year-old post-cardiac surgery patient with excessive mediastinal drainage meeting criteria for antifibrinolytic therapy who receives S0017 administered intravenously in the inpatient setting, documented with indication, dose, and response.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 |